$ISRG

Intuitive Surgical slips as antitrust settlement charge overshadows strong Q3 growth

Intuitive Surgical (ISRG) fell 6.2% after reporting Q3 earnings with a $450M antitrust settlement charge, reducing GAAP net income to $523M from $704M YoY. Revenue grew 22% to $3.05B, and procedures increased 15%. The settlement awaits court approval, adding uncertainty.

Original reporting
Published Oct 20, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Intuitive Surgical slips as antitrust settlement charge overshadows strong Q3 growth — source image
Decision brief

The 30-second read

$ISRGBearishHigh
01

Why it matters

The settlement charge drives immediate sell‑off, but non‑GAAP earnings and procedure volume growth provide a counterbalance.

02

Market read

Earnings with a material legal charge create a clear short‑term trading opportunity.

03

What to watch

Potential upside from continued procedure growth and strong revenue beat may offset the charge over the longer term.

Relevance 8/10Novelty 8/10Timing: after‑hours

Background

Intuitive Surgical reported Q3 2026 results with 22% revenue growth and a $450M antitrust settlement charge.

Company-level read

Ticker impact

$ISRGBearishHigh confidence
Context

Q3 2026 earnings disclosed a $450M pre‑tax antitrust settlement charge, causing a 6.2% share decline.

Expected impact

downward pressure as investors price in the $450M charge and litigation overhang

Evidence & confidence

Large‑cap earnings with a material one‑time charge typically trigger a sustained sell‑off.

Market effects

Robotic surgery peers may see modest pull‑back as investors reassess litigation exposure.

U.S. healthcare sector could face slight downside pressure.

Limited to medical‑device and tech‑health segments.

Counterpoint

Non‑GAAP earnings remain strong; the charge is one‑time, so the stock could rebound on fundamentals.

Key entities

  • Intuitive Surgical

    U.S. medical‑device maker of da Vinci surgical systems.

Related articles

$ISRGMedAI 8/10

Intuitive Surgical, Inc (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported Q3 2026 earnings, highlighting 15% total procedure growth, with 14% in da Vinci and 31% in Ion procedures. U.S. da Vinci growth was 10%, while international growth was 20%. The company installed over 13,200 da Vinci and Ion systems worldwide. Revenue growth was driven by strong demand for da Vinci 5 and SP platforms, with 28% increase in system placements. The company also announced plans for a new manufacturing facility in Malaysia.

$ISRGMedAI 8/10

Intuitive Surgical (ISRG) Q3 Earnings Beat Expectations with Str

Intuitive Surgical (ISRG) reported Q3 earnings that surpassed expectations, with revenue of $3.05B, up 21.5% YoY, and EPS of $3.00. The company saw a 15% rise in procedures and placed 546 new da Vinci systems. ISRG's GF Value suggests it is undervalued by 31.1%, with a GF Score of 96/100. Insiders sold $93.4M in shares, while gurus show mixed activity.

$ISRGHighAI 8/10

Stocks making the biggest moves after hours: Super Micro Computer, Intuitive Surgical, Netflix, SpaceX & more

Intuitive Surgical (ISRG) fell 10% after Q3 results missed expectations, while SpaceX shares rose 2% on a 161% revenue jump. Netflix (NFLX) dropped 5% despite in-line sales. Capital One (COF) gained 5% on higher net income. United Airlines (UAL) declined 2% after earnings trailed estimates. Super Micro Computer (SMCI) surged 12% on an upgraded revenue outlook.